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Summary
Treatment options in subset of patients with high-risk prostate cancer are various: radical prostatectomy, hormonal 
therapy, radiation therapy, combined modality approach, addition of chemotherapy. Based on randomised trials data, 
 optimal approach would consist of radical radiotherapy and long term hormonal therapy. If technically possible high dose 
radiotherapy, hypofractionation, image guided radiotherapy, simultaneous integrated boost on dominant intraprostatic 
lesion and HDR brachytherapy boost should be used as well.
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OPTIMALNA TERAPIJA BOLESNIKA S RAKOM PROSTATE VISOKOG RIZIKA
Sažetak
Kod bolesnika s rakom prostate visokog rizika postoje različite terapijske opcije: radikalna prostatektomija, hormon-
ska terapija, zračenje, združeni pristup, dodatak kemoterapije. Prema rezultatima randomiziranih studija optimalni pristup 
bi bio združena primjena dugotrajne hormonske terapije i zračenja. Ukoliko tehničke mogućnosti dozvoljavaju, trebalo bi 
korisititi zračenje visokim dozama, hipofrakcioniranje, slikom vođenu radioterapiju, simultano integrirano povećanje doze 
na dominantnu intraprostatičnu leziju te primjenom brahiterapije velike brzine doze u kombi naciji s vanjskim zračenjem.
KLJUČNE RIJEČI:  rak prostate visokog rizika, radioterapija, hormonska terapija, zračenje visokim dozama, hipofrakcioniranje, 
simultano integrirano povećanje doze
INTRODUCTION
According to European Association of Urol-
ogy (EAU), high-risk prostate cancer patients are 
defi ned as those with PSA level above 20 ng/mL or 
Gleason score (GS) > 7 (ISUP grade 4/5), or cT2 tu-
mour stage (tumour involves both lobes). cT3 and 
cT4 and N+ stage of the disease is considered lo-
cally advanced (1). According to NCCN guide-
lines high-risk prostate cancer patients are those 
with PSA levels > 20 ng/mL, or GS 4+4 (GG 4) or 
4+5 (GG 5) or cT3a tumour stage (extracapsular 
extension). Patients with cT3b stage (tumour in-
vades seminal vesicle(s)) and cT4 stage, primary 
Gleason patt ern 5 and those who have tumour GS 
8-10 (GG 4-5) in more than 4 cylinders are consid-
ered as very high risk prostate cancer patients (2).
Treatment options in this group of patients 
include radical prostatectomy with pelvic lymph 
node dissection, radiation with androgen depriva-
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tion therapy (external beam radiotherapy or com-
bination of brachytherapy and external beam ra-
diotherapy), combination of radiation, androgen 
deprivation therapy and chemotherapy or just an-
drogen deprivation therapy.
Doubts in radiotherapy in this group of pa-
tients are:
• Whether to use radiotherapy or some other treat-
ment modality
• Should some systemic treatment be used with 
radiotherapy, which one and for how long
• How to perform radiotherapy with regard to 
clinical target volume, radiation dose and frac-
tionation.
TREATMENT OPTIONS
Radical prostatectomy vs. radical radiotherapy
Although many trials have proved superior-
ity of radical prostatectomy compared with radi-
cal radiotherapy, even in patients with high risk 
prostate cancer, those trials are mainly retrospec-
tive population trials with imbalanced patients’ 
populations comparing suboptimal treatment 
methods (Table 1) (3).
In general, patients that underwent radical 
prostatectomy were younger with less co-morbid-
ities, had less aggressive disease, lower PSA levels 
and rarely had locally advanced disease. Shortly, 
studies were biased. Just based on these data and 
without randomised trials, it should not be con-
cluded that radical prostatectomy is undoubtedly 
bett er treatment option than radical radiotherapy 
in this subset of patients (3). According to EAU 
guidelines, radical prostatectomy should be of-
fered to patients with high-risk prostate cancer 
and life expectancy of >10 years only as part of 
multi-modal therapy (1).
Radical radiotherapy
Hormonal therapy vs. combined modality approach: 
hormonal therapy + radical radiotherapy
Lin and associates reported 5- year overall 
survival of patients diagnosed with clinically 
lymph node positive prostate cancer between 2014 
and 2016. One group of patients was irradiated 
and treated with hormonal therapy, while patients 
in the control arm were given hormonal therapy 
only. Each group consisted of 314 patients. Com-
bined modality approach resulted in 50% reduc-
tion of 5-year all cause mortality compared to hor-
monal therapy only. 5- year overall survival was 
86% with radiotherapy and 71% without radio-
therapy. Patients that were irradiated were young-
er, had less co-morbidities, higher PSA values and 
higher GS (GG) (4).
SPCG-7/SFUP-3 trial included 853 patients 
with locally advanced prostate cancer (cT3 in 78% 
of patients) that were receiving life-long hormonal 
therapy: 3 months of complete androgen blockage 
followed by fl utamide. One group of patient re-
ceived radiotherapy. 10 -year cumulative inci-
dence of prostate cancer mortality was 23.9% in 
group that received only hormonal therapy and 
11.9% in group of patients that were also irradiat-
ed. Overall mortality cumulative incidences were 
39.4% and 29.6%, respectively (5).
Trial by Ward and associates included 1205 
patients with high-risk prostate cancer defi ned as 
T3, T4 or T2 with PSA>40 ng/mL or PSA > 20 ng/
Table 1
TRIALS COMPARING RADICAL PROSTATECTOMY WITH RADICAL RADIOTHERAPY IN HIGH-RISK PROSTATE CANCER (3)
Trial Number of patients Population Follow up
Outcome: 
RP better than RT
Cooperberg et al. Cancer 2010 7 539 CaPSURE register, USA 4,2 years Yes
Hoffman et al. JNCI 2013. 1 500 Prostate Cancer Outcome Study, USA 15 years Yes
Abdollah et al. Eur Urol 2011. 404 604 SEER database, USA 5 years Yes
Sun et al. BJU Int 2014. 67 087 SEER Medicare linked database, USA 10 years Yes
Zelefsky et al. J Clin Oncol 2010 2 300 Institutional register, USA 8 years Yes
Nepple et al. Eur Urol 2014. 6 000 2 tertiary centres 7,2 years Yes
Abdollah et al. Int J Urol 2012. 68 665 SEER Medicare linked database, USA unknown Yes
Sooriakumaran et al. BMJ 2014 34 500 PcBaSe, Sweden 5,3 years Yes
Boorijan et al. Cancer 2011 1 800 2 tertiary centres 10,2 years yes
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mL with GS 8 (GG 4) or higher in period 1995-
2005. 602 patients were given only hormonal ther-
apy (surgical castration or LHRH agonist) and 603 
patients were also irradiated. Dose on prostate 
and seminal vesicles was 65 – 69 Gy and dose on 
pelvic lymph nodes 45Gy. Irradiated patients had 
bett er 7- year overall survival: 74% vs. 66% (6).
All these results indicate undoubted advan-
tage of combined modality approach. Hormonal 
therapy as a sole treatment modality should be an 
option just for patients in whom irradiation would 
be contraindicated.
Radiotherapy vs. combined modality approach: 
hormonal therapy + radical radiotherapy
Meta- analysis by Bria published in 2009 in-
cluded 7 trials and showed benefi t of addition of 
hormonal therapy to radiotherapy with regard to 
lower rate of biochemical relapse (10% absolute 
diff erence). Patients receiving hormonal therapy 
had bett er clinical progression free survival (abso-
lute diff erence 7.7%), overall survival (4.9%), tu-
mour specifi c survival (5.5%) and less local and 
distant relapse (diff erence 36% and 27%, respec-
tively) without signifi cant diff erence in toxicity 
between two treatments (7).
However, it is not clear for how long should 
patients with high-risk prostate cancer receive 
hormonal therapy when combined with high dose 
radiotherapy.
Phase 3 randomised trial included 362 pa-
tients with intermediate and high risk prostate 
cancer. Median dose on prostate was 78 Gy. All 
patients received neoadjuvant and concomitant 
hormonal therapy; patients in experimental arm 
continued with goserelin for up to two years. Af-
ter 5 years of follow up patients on long term hor-
monal therapy had statistically signifi cant bett er 
biochemical free survival, overall survival and 
metastases free survival (86 vs. 95%, 89 vs. 94% 
and 85 vs. 93%, respectively). No signifi cant dif-
ference in acute and late toxicity was observed be-
tween groups (8). In conclusion, benefi t of long-
term hormonal treatment still exists, regardless of 
higher radiation dose applied on prostate.
Combined modality approach, meaning ra-
diotherapy with hormonal therapy in patients 
with high- risk prostate cancer is signifi cantly bet-
ter option than either of these two modalities 
alone.
Neoadjuvant chemotherapy with radiotherapy
GETUG 12 trial included 413 patients with 
high- risk prostate cancer that were receiving gos-
erelin for 3 years and had local treatment, which 
in 87% of patients was radiotherapy (doses 74 - 
78Gy). Patients randomised in experimental arm 
of the trial were given 4 cycles of docetaxel with 
estramustine prior to beginning of radiotherapy. 
PSA response, defi ned as PSA level < 0.2 ng/mL 
after 3 months of treatment, was achieved in 34% 
patients in experimental arm and in 15% of pa-
tients in control arm. After 4.6 years of follow up 
4- year progression free survival rates were 85% in 
patients who received docetaxel/estramustine and 
81% in control group (p= 0.26). 27% of patients re-
ceiving chemotherapy experienced neutropenia 
grade 3-4; rate of febrile neutropenia was 2% (9).
Whole pelvis irradiation
It is still unclear whether to include pelvic 
lymph nodes in target volume in this subset of pa-
tients.
When sett ing up an indication either Roach 
formula (N+ = 2/3 PSA + (GS-6) x 10) or nomo-
grams are being used (10). In case the risk of 
lymph node involvement is >15%, whole pelvis 
radiotherapy is indicated. Clinically positive lymph 
nodes on MRI or CT scan are those larger than 10 
mm in shorter diameter or larger than 8 mm, if 
lymph node is round. Choline PET scan has no 
role in lymph nodes involvement evaluation due 
to its low specifi city (1).
Retrospective analysis of RECAP basis data 
involved 670 high-risk prostate cancer patients ir-
radiated between 1993 -1999. 234 patients had just 
prostate irradiation- PORT (doses 55- 82.4 Gy, me-
dian 72 Gy) and 436 patients had also pelvic lymph 
node irradiation- WPRT (36- 56Gy, median 46 
Gy). After median follow up of 77 (WPRT) and 86 
months (PORT), there was no statistically signifi -
cant diff erence between those two groups regard-
ing 5 and 10- year biochemical failure, disease free 
survival, overall survival or cancer specifi c sur-
vival. In WPRT group early gastrointestinal and 
late genitourinary toxicity was more frequently 
observed (11).
High dose radiotherapy
A number of trials evaluated high dose ra-
diotherapy in patients with localised prostate can-
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cer, regardless of the disease stage. Bett er 5- year 
biochemical free survival was observed. Trials are 
summarised on Table 2 (1).
Retrospective NCDB trial has analysed 42 
481 patients’ data: 12 229 low risk, 16 714 interme-
diate risk and 13 538 high risk prostate cancer pa-
tients irradiated between 2004 - 2006. They were 
divided into two groups regarding radiation dose: 
standard dose - 68.4- 75.6 Gy and escalated dose 
– 75.6- 90 Gy. In groups of patients with interme-
diate and high risk prostate cancer, bett er overall 
survival was observed with dose escalation (HR 
0.84 and 0.82, p< 0.001). No benefi t of dose escala-
tion has been shown in group of patients with low 
risk prostate cancer (HR 0.98, p = 0.54). For every 2 
Gy dose increment there was 7.8% reduction of 
death risk in intermediate risk patients and 6.3% 
reduction of death risk in high risk patients (12).
Integrated boost on macroscopic lesion in prostate
Dose escalation leads to bett er outcome in 
patients with high risk prostate cancer, but further 
increment is limited by surrounding tissue toler-
ance. Since prostate cancer relapses occur in area 
where macroscopic tumour is located – dominant 
intraprostatic lesion (DIL), it is reasonable to ap-
ply higher dose on that exact part of prostate us-
ing simultaneous integrated boost (SIB).
FLAME trial included 541 patients with pros-
tate cancer, 84% of which had high risk cancer. In 
experimental arm (284 pts) dose of 77 Gy in 35 
fractions to the entire prostate gland was adminis-
tered with an integrated boost up to 95 Gy to the 
macroscopic lesion. Control arm received 77Gy in 
35 fractions to the entire prostate only. After me-
dian follow up of 22 months data regarding dis-
ease control were still lacking, but data regarding 
toxicity were published. No signifi cant diff erence 
was found between both treatment arms for geni-
tourinary toxicity. Urinary symptoms related to 
quality of life were not signifi cantly diff erent 
across treatment arms (13).
Phase 3 trial by Sundahl included 410 pa-
tients with T1-4N0M0 prostate cancer; 48% of 
them had high risk prostate cancer. Prescribed 
dose on prostate was 78Gy in 38 fractions; patients 
that had visible dominant intraprostatic lesion on 
MRI were given 82 Gy in 38 fractions on that par-
Table 2
DOSE ESCALATION RANDOMISED TRIALS IN LOCALISED PROSTATE CANCER (1)
Trial No of patients Stage
Radiation 
dose Follow-up Outcome Results
MD Anderson
Kuban et al. 
Int J Radiat Oncol 
Biol Phys, 2011
301 T1-3, N0, M0, 
PSA 10 ng/mL vs 
PSA >10 ng/mL
70 vs 78Gy median 
9 years
disease specifi c 
mortality (DSM) 
vs other cause 
of death
high risk: (PSA> 10): 
DSM 16% 70Gy, 4% 78Gy 
(p=0,05)
higher risk DSM 15% 70Gy, 
2% 78Gy (p=0,03)
PROG 95-09
Zietman et al. 










10- year ASTRO 
biochemical failure 
(BCF)
all patients: BF 32% 70,2Gy, 
17% 79,2 Gy (p< 0,0001)
low risk: BF 28% 70,2Gy, 




843 T1b-T3a N0M0, 
PSA<50ng/mL
neoadj. HT






BFS 43% 64Gy, 55% 74Gy 
(p= 0,0003),







164 patients with 
neoadjuvant HT
68 vs 78Gy median 
110 months
biochemical 
(Phoenix defi nition) 
and clinical failure 
free (FFF) 
FFF 43% 68Gy, 49% 78 Gy 
(p= 0,045)
GETUG 06
Beckendorf et al. 
Int J Radiat Oncol 
Biol Phys 2011
306 T1b-3a, N0, M0, 
PSA<50ng/mL




BF 39% 70Gy, 28% 80Gy 
retrospective 
NCDB trial












overall survival (OS) HR 0,84 for dose escalation 
(p<0,001)




ticular area (SIB; dose equivalent 86Gy for α/β 1.5) 
or more, if tolerated by surrounding tissues. No 
diff erence between groups was observed in 6 – 
year risk for development of late grade 2 and 3 
genitourinary or bowel toxicity. After 36, 42, 72 
and 96 months of follow up, in group of patients 
that received SIB higher frequency of urinary in-
continence was noticed (14).
Hypofractionation
Hypofractionation stands for irradiation in 
daily fractions higher than 2 Gy. It is assumed that 
α/β ratio of prostate cancer is about 1.5, which 
makes it sensitive on fraction size. Besides expect-
ed clinical benefi t, hypofractionation lowers num-
ber of radiation sessions, which shortens overall 
treatment time. If doses higher than 4 Gy per frac-
tion are to be applied, it is necessary to use image 
guided radiotherapy (IGRT) or stereotactic irradi-
ation. In published trials short biochemical dis-
ease control is similar between treatment arms but 
long term eff ects on organs at risk (bladder and 
bowel) are not yet completely known, bearing in 
mind short follow up. Phase 3 trials are summa-
rized on Table 3 (1).
In phase 3 CHHip trial 3216 patients with 
prostate cancer T1b-T3aN0M0 were randomised 
in 3 groups with regard to radiation regimen: 74 
Gy in 37 fractions, 60 Gy in 20 fractions and 57 Gy 
in 19 fractions. IMRT and SIB were used. WPRT 
was not performed. 97% of patients received neo-
adjuvant and concomitant hormonal therapy. In 
each group 12% of patients had high risk prostate 
cancer. IGRT was not used in 53% of patients in 
each group. After median follow up of 64 months 
the proportion of patients who were biochemical 
or clinical failure free at 5 years was 88.3 for 74 Gy, 
90.6% for 60 Gy/20 and 85.9% for 57 Gy/19. 60 Gy 
was non- inferior to 74 Gy, but non- inferiority 
could not be claimed for 57 Gy/19 compared with 
74 Gy. No signifi cant diff erence between treat-
ment groups was observed for late toxicity: fre-
quencies of grade 2 and higher bowel and bladder 
adverse reactions were 13.7% and 9.1 % respec-
tively for 74 Gy, 11.9% and 11.7% for 60 Gy/20 and 
11.3% and 6.6% for 57 Gy/19 (15).
HYPRO trial enrolled 820 patients with inter-
mediate-risk to high-risk T1b-T4NX-N0MX-M0 
localised prostate cancer with a PSA of 60 μg/L or 
less. They were randomly assigned (1:1) to either 
hypofractionated radiotherapy of 64.6 Gy (19 frac-
tions of 3.4 Gy, three fractions per week) or con-
ventionally fractionated radiotherapy of 78 Gy (39 
fractions of 2 Gy, fi ve fractions per week). Based 
on an estimated α/β ratio for prostate cancer of 1.5 
Gy, the equivalent total dose in fractions of 2 Gy 
was 90.4 Gy for hypofractionation, compared with 
78 Gy for conventional fractionation. 67% of pa-
tients received concomitant androgen deprivation 
therapy (median duration 32 months). The prima-
ry endpoint was relapse-free survival. After me-
Table 3
PHASE 3 TRIALS – HYPOFRACTIONATION IN PRIMARY RADIOTHERAPY OF PROSTATE CANCER (1)




follow up Outcome Toxicity
Lukka et al. 










68 months 5- year free from 
biochemical failure 
(FFBF)
40 vs 43% (NS)
Gr3
2vs 1% (NS)
Arcangeli et al. 










70 months 5- year FFBF 85 




3 - years Gr2 and higher
GU 16 vs 11% (NS)
GI 17 vs 14% (NS)
Pollack et al










68 months 5- year biochemical 
or clinical disease 
free (BCDF)
23 vs 21% (NS)
5- year Gr2 and higher
GU 13 vs 13% (NS)













49 months no data 3 - months Gr2 and higher
GU 23 vs 22% (NS)
GI 13 vs 13% (NS)
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dian follow-up of 60 months, 5-year relapse-free 
survival was 80.5% for patients assigned hypo-
fractionation and 77.1% for those allocated con-
ventional fractionation. 3 months after radiothera-
py, no diff erence in frequency of grade 2 or worse 
genitourinary or gastrointestinal toxicity was ob-
served between treatment groups. However, the 
cumulative incidence of grade 2 or worse acute 
gastrointestinal toxicity by 120 days after radio-
therapy was higher in patients given hypofrac-
tionation: 42% vs. 31.2% in the standard fraction-
ation group. There were no treatment-related 
deaths (16, 17).
NCI Canada trial randomized 936 patients 
with cT1-T2 prostate cancer whose PSA levels 
were <40 μg/L to either hypofractionated radio-
therapy of 52.5 Gy (2.62 Gy per fraction) or con-
ventionally fractionated radiotherapy of 66 Gy (33 
fractions of 2 Gy). 20% of patients in each treat-
ment arm had PSA level 15 μg/L or higher, there-
fore could be defi ned as high- risk patients. The 
primary outcome was biochemical or clinical fail-
ure (BCF). Median follow up was 5.7 years. At 5 
years, the BCF probability was 52.95% in the long 
arm and 59.95% in the short arm, favouring the 
long arm. No diff erence in 2-year postradiothera-
py biopsy or in overall survival was detected be-
tween the arms. Acute toxicity was higher in the 
short arm (11.4%) compared with the long arm 
(7%). However, late toxicity was similarly low in 
both arms (3.2%). It is to be noticed that patients 
did not receive concomitant androgen deprivation 
therapy and that prescribed doses were much 
lower than those prescribed nowadays. (18).
HDR brachytherapy as boost
In patients with high-risk prostate cancer 
high dose rate (HDR) brachytherapy could be 
used as a dose escalating boost delivered in com-
bination with external beam radiotherapy. Iridi-
um-192 (IR-192) isotope is being introduced 
through implanted needles or catheters. Radiation 
dose is delivered in minutes, implantation is tem-
porary and there are no radiation protection is-
sues for patient or carers. Patients with signifi cant 
urinary outfl ow symptoms are not candidates for 
HDR boost (19, 1).
A randomised phase-III trial compared exter-
nal beam radiotherapy (EBRT) alone with EBRT 
combined with high-dose-rate brachytherapy boost 
(HDR-BTb) in 218 patients with localised prostate 
adenocarcinoma. About 50% of patients in each 
arm had high- risk prostate cancer. Patients in 
EBRT arm received a total dose of 55 Gy in 20 dai-
ly fractions while patients in HDR-BTb arm re-
ceived EBRT 35.75 Gy in 13 fractions followed by 
HDR-BT boost of 2x 8.5 Gy in 24 h. Biochemical/
clinical relapse-free survival (RFS) was the prima-
ry endpoint. Secondary endpoints were overall 
survival (OS), urinary and bowel toxicity. After 4 
years median time to relapse was 116 months in 
EBRT + HDR-BTb group, compared to 74 months 
in EBRT only group. (log rank p = 0.04). In multi-
variate analysis treatment arm, risk category and 
ADT were signifi cant covariates for risk of relapse. 
Diff erences in OS were not signifi cant. Incidence 
of severe late urinary and bowel morbidity was 
similar: the 5 and 7 year incidence for patients 
with any severe urinary symptom was 26% and 
31% for those treated with EBRT + HDR-BTb com-
pared with 26% and 30% for patients in EBRT only 
arm (log rank p = 0.5). The incidence of severe 
bowel events was 7% and 6%, respectively, at 5 
and 7 years; (log rank p = 0.8) (20).
CONCLUSION
According to literature, recommended thera-
py for high risk prostate cancer patients would be 
high dose radical radiotherapy with long term 
hormonal therapy. Depending on each centre ex-
perience as well as technical possibilities, use of 
simultaneous integrated boost, brachytherapy 
HDR boost or hypofractionation should be taken 
into consideration.
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